GSK, Shenzhen Neptunus Of China To Collaborate On Flu Vaccines
This article was originally published in PharmAsia News
Executive SummaryU.K.-based GlaxoSmithKline and China's Shenzhen Neptunus plan a joint venture to make influenza vaccines in China, with GSK holding a 40 percent stake with options to buy more. The deal is expected to increase the British company's presence in China where it hopes to trade on its adjuvant technology. The five-year plan for the joint venture calls for production of seasonal, pre-pandemic and pandemic flu vaccine for China, Hong Kong and Macau. GSK also intends to expand its vaccine-manufacturing business in other parts of Asia. (Click here for more
You may also be interested in...
Komipharm files for emergency clinical trial of its investigative drug to treat coronavirus pneumonia, which is poised to become the first such study by a Korean company.
Apple and Johnson & Johnson are recruiting patients into Heartline, a 150,000-patient "virtual" randomized study to evaluate how the Apple watch can improve patient outcomes by reducing risk of stroke and detect atrial fibrillation early. See what Heartline's co-chair Michael Gibson of Harvard University said about it here.
After eptinezumab’s approval in the US, EVP Peter Anastasiou told Scrip it will take time to change migraine doctors’ prescribing habits, but he expects CGRP inhibitors to become mainstay preventative treatments. Vyepti’s list price is about $1,000 below its competitors’ launch prices.